Leo Gordon is an Oncology physician. ClinicalTrials.gov lists 13 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
675 N Saint Clair St
Galter 21-100
Chicago, IL 606115975
Telephone
312-695-0990Provider last certified this registry record 6 Jan 2025.
Clinical trials
- Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor: National Cancer Institute (NCI)
- CT-011 MAb in DLBCL Patients Following ASCT
Sponsor: CureTech Ltd
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20242 payments
- Genentech USA, Inc.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.3%CD38-directed Cytolytic Antibody43.4%Daratumumab100%Part B, office-administered≥16 patientsProteasome Inhibitor7%Bortezomib100%Part B, office-administered≥14 patients+ 2 more classes in this area
Dermatology
22.8%Corticosteroid22.4%Methylprednisolone sodium succinate100%Part B, office-administered≥14 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.5%Acyclovir100%Part D≥13 patientsAnti-infectives
20.8%Human Immunoglobulin G20.4%Immune globulin100%Part B, office-administered≥22 patientsShort-acting sulfonamides0.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1991–2001 per NIH RePORTER. The latest:
- IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
Northwestern University
FY2001M01RR000048 - IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
Northwestern University
FY2001M01RR000048 - IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
Northwestern University
FY2001M01RR000048
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”